Universal Biosensors (ASX:UBI) LT-Debt-to-Total-Asset : 0.09 (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Universal Biosensors LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Universal Biosensors's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.09.

Universal Biosensors's long-term debt to total assets ratio declined from Dec. 2023 (0.11) to Dec. 2024 (0.09). It may suggest that Universal Biosensors is progressively becoming less dependent on debt to grow their business.

Universal Biosensors LT-Debt-to-Total-Asset Historical Data

The historical data trend for Universal Biosensors's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Biosensors LT-Debt-to-Total-Asset Chart

Universal Biosensors Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.04

0.09

0.11

0.09

Universal Biosensors Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.11	0.08	0.09	0.09

Universal Biosensors LT-Debt-to-Total-Asset Calculation

Universal Biosensors's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	2.402	/	25.841
	=	0.09

Universal Biosensors's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	2.402	/	25.841
	=	0.09

Universal Biosensors (ASX:UBI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Universal Biosensors LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Universal Biosensors's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Biosensors Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Universal Biosensors Inc (ASX:UBI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Corporate Avenue, Rowville, VIC, AUS, 3178

Website

https://www.universalbiosensors.com

Universal Biosensors Inc is biosensor company in electrochemical cell technology to develop a diverse range of biosensor test strips. The company's platform develops a diverse range of biosensor test strips used in conjunction with point-of-use devices that are used in various industries such as healthcare (point-of-care), wine, food and agriculture. It manufactures and distributes PT-INR coagulation test strips and devices, Xprecia, Stride and Xprecia Prime which are medical devices, Sentia non-medical wine testing products, and Petrackr which is a blood glucose test used in cats and dogs. It has one reportable segment: specialist biosensors company. Geographically, the company generates majority of its revenue from Australia and rest from Americas, Europe and other markets.

Universal Biosensors Headlines

No Headlines